The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Venous thromboembolism (VTE) Therapeutics Market Research Report 2025
Synopsis
Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE
The global Venous thromboembolism (VTE) Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Venous thromboembolism (VTE) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Venous thromboembolism (VTE) Therapeutics.
Report Scope
The Venous thromboembolism (VTE) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Venous thromboembolism (VTE) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Venous thromboembolism (VTE) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boehringer Ingelheim
Bayer
Janssen
Bristol-Myers Squibb
Pfizer
Daiichi-Sankyo
Portola Pharmaceuticals
Armetheon
Segment by Type
Deep Vein Thrombosis(DVT)
Pulmonary Embolism(PE)
Others
Segment by Application
Hospital
Ambulatory Surgery Centers
Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Venous thromboembolism (VTE) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE
The global Venous thromboembolism (VTE) Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Venous thromboembolism (VTE) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Venous thromboembolism (VTE) Therapeutics.
Report Scope
The Venous thromboembolism (VTE) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Venous thromboembolism (VTE) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Venous thromboembolism (VTE) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boehringer Ingelheim
Bayer
Janssen
Bristol-Myers Squibb
Pfizer
Daiichi-Sankyo
Portola Pharmaceuticals
Armetheon
Segment by Type
Deep Vein Thrombosis(DVT)
Pulmonary Embolism(PE)
Others
Segment by Application
Hospital
Ambulatory Surgery Centers
Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Venous thromboembolism (VTE) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Venous thromboembolism (VTE) Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Deep Vein Thrombosis(DVT)
1.2.3 Pulmonary Embolism(PE)
1.2.4 Others
1.3 Market by Application
1.3.1 Global Venous thromboembolism (VTE) Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Ambulatory Surgery Centers
1.3.4 Research Institutes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Venous thromboembolism (VTE) Therapeutics Market Perspective (2019-2030)
2.2 Venous thromboembolism (VTE) Therapeutics Growth Trends by Region
2.2.1 Global Venous thromboembolism (VTE) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Venous thromboembolism (VTE) Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Venous thromboembolism (VTE) Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Venous thromboembolism (VTE) Therapeutics Market Dynamics
2.3.1 Venous thromboembolism (VTE) Therapeutics Industry Trends
2.3.2 Venous thromboembolism (VTE) Therapeutics Market Drivers
2.3.3 Venous thromboembolism (VTE) Therapeutics Market Challenges
2.3.4 Venous thromboembolism (VTE) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Venous thromboembolism (VTE) Therapeutics Players by Revenue
3.1.1 Global Top Venous thromboembolism (VTE) Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Venous thromboembolism (VTE) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Venous thromboembolism (VTE) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Venous thromboembolism (VTE) Therapeutics Revenue
3.4 Global Venous thromboembolism (VTE) Therapeutics Market Concentration Ratio
3.4.1 Global Venous thromboembolism (VTE) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Venous thromboembolism (VTE) Therapeutics Revenue in 2023
3.5 Venous thromboembolism (VTE) Therapeutics Key Players Head office and Area Served
3.6 Key Players Venous thromboembolism (VTE) Therapeutics Product Solution and Service
3.7 Date of Enter into Venous thromboembolism (VTE) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Venous thromboembolism (VTE) Therapeutics Breakdown Data by Type
4.1 Global Venous thromboembolism (VTE) Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Venous thromboembolism (VTE) Therapeutics Forecasted Market Size by Type (2025-2030)
5 Venous thromboembolism (VTE) Therapeutics Breakdown Data by Application
5.1 Global Venous thromboembolism (VTE) Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Venous thromboembolism (VTE) Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Venous thromboembolism (VTE) Therapeutics Market Size (2019-2030)
6.2 North America Venous thromboembolism (VTE) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Venous thromboembolism (VTE) Therapeutics Market Size by Country (2019-2024)
6.4 North America Venous thromboembolism (VTE) Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Venous thromboembolism (VTE) Therapeutics Market Size (2019-2030)
7.2 Europe Venous thromboembolism (VTE) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Venous thromboembolism (VTE) Therapeutics Market Size by Country (2019-2024)
7.4 Europe Venous thromboembolism (VTE) Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Venous thromboembolism (VTE) Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Venous thromboembolism (VTE) Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Venous thromboembolism (VTE) Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Venous thromboembolism (VTE) Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Venous thromboembolism (VTE) Therapeutics Market Size (2019-2030)
9.2 Latin America Venous thromboembolism (VTE) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Venous thromboembolism (VTE) Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Venous thromboembolism (VTE) Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Venous thromboembolism (VTE) Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Venous thromboembolism (VTE) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Venous thromboembolism (VTE) Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Venous thromboembolism (VTE) Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Company Detail
11.1.2 Boehringer Ingelheim Business Overview
11.1.3 Boehringer Ingelheim Venous thromboembolism (VTE) Therapeutics Introduction
11.1.4 Boehringer Ingelheim Revenue in Venous thromboembolism (VTE) Therapeutics Business (2019-2024)
11.1.5 Boehringer Ingelheim Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Venous thromboembolism (VTE) Therapeutics Introduction
11.2.4 Bayer Revenue in Venous thromboembolism (VTE) Therapeutics Business (2019-2024)
11.2.5 Bayer Recent Development
11.3 Janssen
11.3.1 Janssen Company Detail
11.3.2 Janssen Business Overview
11.3.3 Janssen Venous thromboembolism (VTE) Therapeutics Introduction
11.3.4 Janssen Revenue in Venous thromboembolism (VTE) Therapeutics Business (2019-2024)
11.3.5 Janssen Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Venous thromboembolism (VTE) Therapeutics Introduction
11.4.4 Bristol-Myers Squibb Revenue in Venous thromboembolism (VTE) Therapeutics Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Venous thromboembolism (VTE) Therapeutics Introduction
11.5.4 Pfizer Revenue in Venous thromboembolism (VTE) Therapeutics Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Daiichi-Sankyo
11.6.1 Daiichi-Sankyo Company Detail
11.6.2 Daiichi-Sankyo Business Overview
11.6.3 Daiichi-Sankyo Venous thromboembolism (VTE) Therapeutics Introduction
11.6.4 Daiichi-Sankyo Revenue in Venous thromboembolism (VTE) Therapeutics Business (2019-2024)
11.6.5 Daiichi-Sankyo Recent Development
11.7 Portola Pharmaceuticals
11.7.1 Portola Pharmaceuticals Company Detail
11.7.2 Portola Pharmaceuticals Business Overview
11.7.3 Portola Pharmaceuticals Venous thromboembolism (VTE) Therapeutics Introduction
11.7.4 Portola Pharmaceuticals Revenue in Venous thromboembolism (VTE) Therapeutics Business (2019-2024)
11.7.5 Portola Pharmaceuticals Recent Development
11.8 Armetheon
11.8.1 Armetheon Company Detail
11.8.2 Armetheon Business Overview
11.8.3 Armetheon Venous thromboembolism (VTE) Therapeutics Introduction
11.8.4 Armetheon Revenue in Venous thromboembolism (VTE) Therapeutics Business (2019-2024)
11.8.5 Armetheon Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
